Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Stryker (SYK – Research Report) yesterday and set a price target of $435.00.
Larry Biegelsen has given his Buy rating due to a combination of factors including strategic business decisions and financial projections. The recent acquisition of Inari and the anticipated sale of Stryker’s spine business are expected to influence the company’s financial performance positively.
Despite a slight decrease in the 2025 revenue estimate and a minor reduction in the full-year EPS forecast, the overall growth outlook remains strong with an expected revenue of approximately $24.4 billion, reflecting an 8.1% year-over-year increase. These strategic moves and the anticipated growth trajectory underpin the Buy rating for Stryker’s stock.
According to TipRanks, Biegelsen is a 5-star analyst with an average return of 11.3% and a 61.20% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Dexcom, and Intuitive Surgical.
In another report released on February 26, Citi also initiated coverage with a Buy rating on the stock with a $450.00 price target.